Innovent Biologics' Lung Cancer Drug Hets NDA Approval From China's NMPA

MT NewswiresDec 23 15:09

Express News | Innovent Receives Approval of Dovbleron® (Taletrectinib Adipate Capsule, Ros1 Inhibitor) by China's National Medical Products Administration

BreakingsDec 20 20:10

INNOVENT BIO (01801.HK): The ROS1 inhibitor Dabolat (Dabrafenib capsules) has been approved for marketing by the National Medical Products Administration.

Glory Financial reported on December 20th that INNOVENT BIO (01801.HK) announced the approval from the National Medical Products Administration (NMPA) of China for the new drug application (NDA) of the new generation ROS1 tyrosine kinase inhibitor (TKI) Daborin (Dabrefenib capsules) for the treatment of adult patients with ROS1-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have progressed after treatment with ROS1-TKI. Daborin is the company's 13th commercial product, and this innovative precision therapy will benefit lung cancer patients with ROS1 mutations, further strengthening the company's position in tumor precision.

Gelonghui FinanceDec 20 19:16

Market quick glance | The three major Indices showed mixed results, with the tech index slightly rising, Xiaomi and Tencent increasing nearly 3%; Semiconductors stocks were strong, with Semiconductor Manufacturing International Corporation rising over 8%;

Network Technology stocks performed poorly, KUAISHOU-W fell by 5.42%, Alibaba-W dropped by 3.44%; most Coal Industrial Concept stocks declined, SOUTHGOBI fell by 12.02%, China Coal Energy dropped by 6.37%; many Hong Kong Retail Stocks fell, PRADA decreased by 3.80%, BOSSINI INT'L dropped by 3.48%;

Futu NewsDec 20 16:23

Bank of America Securities: Reiterates Buy rating for INNOVENT BIO (01801) and HANSOH PHARMA (03692) with both Target Prices raised.

INNOVENT BIO (01801) recently reached a commercialization agreement with Eli Lilly and Co (LLY.US) for its non-covalent (reversible) BTK inhibitor "Jepalibri" in mainland China.

Zhitong FinanceDec 20 11:47 · Ratings

Bank of America Merrill Lynch has lowered the Target Price for Shanghai Pharmaceuticals (01093.HK) to 4.6 yuan and raised the Target Price for INNOVENT BIO (01801.HK) to 56.4 yuan.

Merrill Lynch Securities released a Research Report stating that CSPC PHARMA (01093.HK) and BEIGENE (06160.HK) have reached a global exclusive licensing agreement for the group's novel methionine adenosyltransferase 2A (MAT2A) inhibitor SYH2039 and subsequent development. Taking into account the aforementioned collaboration and the recent bidding results of the tenth batch of national organization pharmaceutical centralized procurement, the revenue forecasts for CSPC PHARMA for 2024 to 2026 have been adjusted down by 0.8%, up by 1.7%, and down by 1.7%, respectively, while the earnings per share forecasts have been adjusted down by 0.9%, up by 10.5%, and down by 1.9%. Considering CSPC PHARMA's core product Enbrel.

AASTOCKSDec 20 09:44